This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For their study, the team led by bioinformatics professor Andreas Keller and his doctoral student […]. Credit: Oliver Dietze In their study, which is now published in the journal Nature Aging, they show that the level of non-coding RNAs in the blood of a Parkinson’s patient can be used to track the course of the disease.
Biotech company Ultima Genomics has joined forces with Genome Insight, a bioinformatics-based biomedicine company, to overcome the caveat of cost and quality in WGS. Genome sequencing requires a powerful sequencer to decode the genetic makeup and an equally powerful analysis platform to make sense of the data generated.
Doctors and physicians rely on the results provided by a clinical scientist to make an accurate prognosis, diagnosis and assessment for a patient’s treatment plan. Interpret medical tests and confer with doctors and physicians for a suitable prognosis and treatment plan. Genetic Science. Respiratory Physiology. Microbiology.
But they said the sum covers only the direct costs of designing and manufacturing the vaccines ― which are tailored to the unique genetic makeup of each patient’s tumor ― and that the FDA has approved the breakdown of expenses. A doctor at Duke was skeptical and would not administer the shots, Kielty said.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content